

# Cardiology Research Newsletter

Summer 2015 • Issue Four



## ***New In Cardiovascular Surgery Research***

### **LEVO-CTS Trial**

Tenax Therapeutics, Inc.

*James Anton, MD, Principal Investigator*

This is a phase 3 trial for Levosimendan (Simdax®), a double-blind, randomized, placebo-controlled study that will evaluate the use of levosimendan administered before and during cardiac surgery to reduce the incidence of low cardiac output syndrome (LCOS) and associated morbidity and mortality. Patients must have LVEF  $\leq 25\%$  and be scheduled for CABG or LVEF  $\leq 35\%$  and scheduled for CABG with aortic valve, CABG with mitral valve, or isolated mitral valve surgery. Contact [ocr@stlukeshhealth.org](mailto:ocr@stlukeshhealth.org) or call 832-355-3710 for complete criteria.

### **LIFE Study**

Trivascular, Inc.

*Zvonimir Krajcer, MD, Principal Investigator*

The LIFE Study: Least Invasive Fast-Track EVAR with the Ovation Prime Abdominal Stent Graft System is a prospective, consecutively enrolling, non-randomized multi center post-market registry to evaluate the ultra-low profile (14F) Ovation Prime Abdominal stent Graft System when used in the Percutaneous Endovascular Aneurysm Repair (PEVAR) treatment of patients with AAA using a Fast-Track EVAR protocol. Contact [ocr@stlukeshhealth.org](mailto:ocr@stlukeshhealth.org) or call 832-355-3710 for complete protocol information.

### **PORTICO Trial**

St. Jude Medical, Inc.

*Joseph Coselli, MD, Principal Investigator*

The PORTICO clinical trial is a prospective, multi-center, randomized, controlled clinical study, designed to evaluate the safety and effectiveness of the SJM Portico Transcatheter Heart Valve and Delivery Systems (Portico) via the transfemoral and alternative delivery method in patients that have been diagnosed with severe aortic stenosis. With a

composite endpoint of all cause mortality or disabling stroke at one year, the PORTICO trial will include a maximum of 1610 subjects (930 subjects in the high risk cohort and 680 subjects in the extreme risk cohort. To obtain inclusion and exclusion criteria for valve studies, contact the Research Coordinator at 832-355-9301.

## **Stem Cell Research**

### **PACE**

Cardiovascular Cell Therapy Research Network (CCTRN)

*Emerson C. Perin, MD, Principal Investigator*

This is a randomized, double-blind, placebo-controlled trial that will assess the potential physiologic effect, clinical efficacy, and safety of autologous bone marrow derived aldehyde dehydrogenase bright cells delivered by intramuscular injections to patients with PAD and symptom-limited intermittent claudication. Contact [ichambers@texasheart.org](mailto:ichambers@texasheart.org) or call 832-355-9405 for complete protocol information.

## **More News**

### **BSLMC 8<sup>th</sup> Annual Clinical Research Symposium**

Thank you to all of the cardiovascular research speakers for their presentations at the 8<sup>th</sup> Annual Clinical Research Symposium that was held on May 19<sup>th</sup> in the Denton A. Cooley Auditorium. Over 100 participants of the event benefited from educational and entertaining presentations from Drs. William Cohn, Zvonimir Krajcer, Wei Pan, Emerson Perin, and David Sugarbaker on their latest developments in CV research at BSLMC.

### **Pearland Community Health Screenings**

CHI St. Luke's Health recently coordinated health screening events at two Pearland area locations, Glenda Dawson High School on April 18<sup>th</sup> and Pearland High School May 16<sup>th</sup>, 2015. Volunteers from CHI St. Luke's and Baylor College of Medicine helped screen over 800 children and adults from the Pearland area. The free of charge health screenings included physical exams, echocardiograms, electrocardiograms, blood pressure checks, body mass index (BMI) measurements, glucose & cholesterol tests, and consultation with a cardiologist.

Kathryn Dougherty, Clinical Research Specialist at Baylor St. Luke's and sixth time organizer of this event stated, several cardiac abnormalities were detected during the health screenings. Participants identified with abnormalities were offered further testing including the cardiac MRI study being conducted by Texas Heart Institute.

# **REMINDER!**

## **Quarterly Cardiovascular Research Meetings**

The quarterly CV research meetings are open to all investigators participating in research at BSLMC.

### **Future Meeting Dates:**

Friday, August 21, 2015

7:30 – 8:30am

Cath Lab Conf Room O609C

Friday, December 18, 2015

7:30 – 8:30am

Cath Lab Conf Room O609C

*Send meeting agenda items to*

[ocr@stlukeshealth.org](mailto:ocr@stlukeshealth.org)